Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation by Arias Barquet, Lluís et al.
© 2016 Arias et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Clinical Ophthalmology 2016:10 861–869
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
861
O r i g i n a l  r e s e a r C h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OPTH.S106092
ranibizumab in monotherapy and combined with 





1Ophthalmology Department, Bellvitge 
University hospital, C/Feixa llarga, 
l’hospitalet de llobregat, Barcelona, 
2spanish Vitreoretinal society (serV), 
C/Xosé Chao rego, santiago de 
Compostela, 3reTiCs OFTareD, 
institute of health Carlos iii, C/
sinesio Delgado, Madrid, 4gómez-Ulla 
eye institute, santiago de Compostela, 
5Department of Ophthalmology, 
albacete University hospital, avenida 
de almansa s/n, albacete, spain
Purpose: To compare the effects of intravitreal ranibizumab in monotherapy (group A) and 
combined with photodynamic therapy (PDT) with verteporfin (group B) in retinal angiomatous 
proliferation (RAP) treatment.
Methods: This was a multicentric, prospective, randomized clinical study conducted with 
parallel groups. The study eye in both groups received ranibizumab on days 1, 30, and 60 (loading 
dose); group B received PDT additionally on day 1. Early Treatment Diabetic Retinopathy 
Study (ETDRS) visual acuity (VA) testing and optical coherence tomography were performed 
monthly, and fluorescein angiography and indocyanine green angiography were performed 
quarterly. Retreatment criteria were leakage in fluorescein angiography or indocyanine green 
angiography, mean foveal thickness increase $100 µm, or VA decrease $5 letters.
Results: Twenty patients were recruited (ten patients in each group). Six eyes had previous 
treatment (three eyes in group A and three eyes in group B), so only 14 eyes were naïve. At 
12-month follow-up, mean VA improved +1.5 letters in group A and +5.6 letters in group B 
(analysis of variance test; P.0.05). Two patients (20%) in both groups gained $15 letters 
(chi-square test; P.0.05). Mean changes in greatest linear dimension and in foveal thickness 
were not statistically significant between groups of treatment (analysis of variance test; P.0.05). 
Mean retreatments per patient were 1.8 (group A) and 0.9 (group B) (Mann–Whitney U-test; 
P.0.05). One patient died due to underlying disease not related to study medication.
Conclusion: Intravitreal ranibizumab administered in monotherapy or combined with PDT 
was efficacious in terms of VA stabilization in patients with RAP.
Keywords: age-related macular degeneration, intravitreal injection, photodynamic therapy, 
ranibizumab, retinal angiomatous proliferation, verteporfin
Introduction
Retinal angiomatous proliferation (RAP) has recently been described as a variant 
of exudative-type age-related macular degeneration (ARMD), characterized by the 
initial presence of new intraretinal capillaries that grow toward the subretinal space 
and choroid.1–3
Three stages of the disease are distinguished: stage I, characterized by the pres-
ence of intraretinal neovascularization; stage II, in which new capillaries are formed 
in the subretinal space (subretinal neovascularization); and stage III, characterized by 
choroid neovascularization (CNV) with retinochoroidal anastomosis.1
Approximately 10%–15% of all eyes with exudative ARMD present RAP.1,4,5 
The diagnosis of RAP is complex, since in most cases, fluorescein angiography 
(FA) is used, revealing a blurred area of exudate within the intra- or subretinal space 
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that is usually classified as occult CNV. In this context, 
angiography with indocyanine green (ICG) is recommended 
for clear identification. Given the difficulty of its detection, 
it is estimated that RAP could represent almost a quarter 
of all cases of occult or minimally classical CNV.1,6 The 
natural course of RAP differs from that in typical exuda-
tive ARMD, and its prognosis in relation to treatment 
response is poorer.7,8
Different therapeutic approaches have been evaluated in 
RAP treatment,9,10 such as surgery,11,12 laser photocoagulation,8 
transpupillary thermotherapy,13 photodynamic therapy 
(PDT) with verteporfin,14–16 and the intravitreous injection 
of triamcinolone,12,17 among others. More recently, several 
studies have been published which analyze the efficacy of 
antiangiogenic drugs in monotherapy18–21 or in combination 
with other treatments,22–24 revealing visual improvement in 
certain cases.
Nowadays, there is no evidence to support higher efficacy 
with one treatment strategy over the rest, since no random-
ized, controlled clinical trials assessing long-term efficacy 
have been conducted.9 Ranibizumab, which is administered 
as an intravitreal injection, is an antiangiogenic drug that 
has shown efficacy and safety for the treatment of wet 
ARMD.9,18,22–24 Ranibizumab is a humanized monoclonal 
antibody fragment designed to inhibit VEGF-A, a key pro-
tein in angiogenesis, preventing the growth of new blood 
capillaries and leakage.25,26
Ranibizumab has been used for the treatment of retinal 
angiomatous proliferation (RAP) lesions as well, exhibit-
ing a similar profile in comparison with regular ARMD 
lesions.18,19,24
In the case of PDT, following luminous activation after 
the intravenous injection of a photosensitive drug, endothelial 
damage is induced that favors localized platelet adhesion, 
resulting in occlusion of the anomalous vessels with selec-
tive sealing of the neovascularization – without affecting the 
proximal neurosensory retinal layer. PDT with verteporfin 
has been shown to be effective in the treatment of CNV 
associated with exudative ARMD.16
The existing data suggest that combined administration 
of PDT with verteporfin and an antiangiogenic or anti-
inflammatory drug could offer advantages over monotherapy, 
slowing or completely arresting the neovascularization 
process found in RAP.22,24
The purpose of the present study was to obtain efficacy 
and safety data on ranibizumab in monotherapy and in com-
bination with PDT with verteporfin for the treatment of RAP 
during 1 year of follow-up.
Methods
study design
A randomized, open-label, multicenter, parallel-group 
study was designed, considering the inclusion of a total 
of 30 patients with RAP (15 in each treatment group). 
The following groups were established: group A (ranibi-
zumab [Lucentis®; Novartis, Basel, Switzerland] 0.5 mg in 
monotherapy, administered as an intravitreal injection) and 
group B (combination of ranibizumab 0.5 mg and PDT with 
verteporfin [Visudyne®; Novartis, Basel, Switzerland]). The 
patients were randomized in 1:1 proportion to treatment on 
a stratified basis according to the stage of RAP. In group B, 
PDT treatment was guided both by FA and indocyanine green 
angiography (ICGA).
The study included patients aged $50 years, diagnosed 
with RAP in stages I–III, with best-corrected visual acu-
ity (BCVA) in the study eye between 73 and 24 letters, 
measured by Early Treatment Diabetic Retinopathy Study 
(ETDRS) charts at a distance of 4 m or Snellen equivalent. 
Written informed consent was obtained from all cases before 
inclusion in the study. Patients receiving topical or systemic 
steroids or PDT with verteporfin in the study eye during 
the three previous months or antiangiogenic treatment dur-
ing the six previous months were excluded from the study. 
Subjects with cataracts in the study eye that were likely 
to require surgery during the study period, patients with a 
history of glaucoma in the study eye or with an intraocular 
pressure $23 mmHg or with uncontrolled arterial hyperten-
sion (systolic blood pressure .180 mmHg and/or diastolic 
blood pressure .100 mmHg), women of childbearing 
potential not using effective contraceptive methods, as well 
as pregnant and nursing women or women with suspected 
pregnancy were also excluded.
The study was approved by the ethics committees of 
all participating centers and authorized by the Spanish 
Agency for Medicines and Medical Devices. The study 
was conducted in accordance with the principles of the 
Declaration of Helsinki.
Treatment scheme
Table 1 shows the treatment scheme followed in both 
groups. Group A received ranibizumab 0.5 mg on days 1, 
30, and 60 of the trial (loading phase). In addition, group B 
also received PDT with verteporfin on day 1. When needed, 
patients in both groups received retreatment in case of leak-
age detected on FA or ICGA, loss of over five letters in 
visual acuity (VA), or a mean increase in macular thickness 
of $100 µm as measured by optical coherence tomography 







































































































































































































































































































































































































































































(OCT). All retreatments in group B consisted of combined 
therapy of a single intravitreal injection of ranibizumab and 
PDT with verteporfin. In addition, in group B, ranibizumab 
0.5 mg could be administered in monotherapy as rescue 
therapy, if necessary.
Efficacy and safety evaluation
The efficacy of treatment was determined through monthly 
ETDRS chart evaluation of VA and OCT. FA and ICG were 
performed every 3 months.
Safety was assessed by clinical examination and comple-
mentary ophthalmological tests. All reported adverse events 
(AEs) occurring during the clinical trial, as well as concomi-
tant medication were recorded.
statistical analysis
Given the exploratory nature of the study, the efficacy analysis 
was carried out with an intent-to-treat sample including the 
randomized patients who had received at least one treatment, 
with baseline and one posttreatment assessment of the principal 
study variable, BCVA – the last observation carried forward 
method was applied to estimate the missing values. The safety 
sample, in turn, comprised all patients included in the trial who 
had received at least one dose of the study drug.
The categorical variables were described as absolute and 
relative frequencies, while the continuous variables were 
reported as mean, median, standard deviation, and range. 
Comparison of the quantitative variables was based on the 
use of parametric (Student’s t-test or analysis of variance 
[ANOVA]) or nonparametric tests (Mann–Whitney U-test), 
depending on the characteristics of the study variables. 
The chi-square test was used to compare the categorical 
variables. All statistical calculations were performed using 
the Statistical Analysis Software Version 9.1.3 (SAS Institute 
Inc., Cary, NC, USA), applying two-tailed tests, with a level 
of significance of 0.05.
Results
Description of the patient baseline 
characteristics
A total of 20 patients (20 eyes under study) were included in 
the trial, and all were evaluable for efficacy (intent-to-treat 
sample) and safety analysis. Patients were randomized to 
therapy, with ten eyes evaluated in each group.
Table 2 shows the demographic and clinical character-
istics related to the study disease at baseline, according to 
treatment groups. Seven patients (70%) in group A were 
females and six patients (60%) in group B were males. The 





Table 2 Demographic and clinical baseline characteristics of each group
Group A (n=10) Group B (n=10) P-value
Sex, n (%)*
Male 3 (30.0) 6 (60.0) 0.3698
Female 7 (70.0) 4 (40.0)
Age, years (mean ± SD)* 79.5±8.0 79.2±3.7 0.9702
RAP stage, n (%)*
i 2 (20.0) 3 (30.0) 1.0000
ii 6 (60.0) 5 (50.0)
iii 2 (20.0) 2 (20.0)
Angiographic lesion dimensionsł
greatest linear dimension, µm (mean ± sD) 3,827.6±1,370.2 3,297.7±1,740.7 0.4965
Total area of lesion, mm2 (mean ± sD) 8.4±6.1 9.3±7.7 1.0000
Total area of CnV, mm2 (mean ± sD) 1.9±1.6 2.3±1.9 1.0000
Optical coherence tomographył
Foveal thickness, µm (mean ± sD) 438.7±86.6 361.5±81.2 0.0891
Fluorescein angiographic pattern of CNV, n (%)*
Predominantly classic 1 (10.0) 1 (10.0) 1.0000
Minimally classic 5 (50.0) 4 (40.0) 0.6499
Occult 4 (40.0) 5 (50.0) 0.6499
CNV location, n (%)*
subfoveal 2 (20.0) 4 (40.0) 0.6285
Juxtafoveal 4 (40.0) 3 (30.0) 1.0000
extrafoveal 4 (40.0) 3 (30.0) 1.0000
Best-corrected visual acuity in study eyeł
number of letters (mean ± sD) 53.5±15.6 56.1±11.7 0.7653
Tonometrył
intraocular pressure, mmhg (mean ± sD) 15.4±2.7 16.5±3.4 0.6230
Previous treatment, n (%) 3 (30.0) 3 (30.0) 1.0000
PDT¥ 2 (20.0) 1 (10.0) 1.0000
anecortave acetate¥ 1 (10.0) 0–
Bevacizumab§ 3 (30.0) 2 (20.0)–
ranibizumab§ 0 1 (10.0)–
Notes: Group A: ranibizumab; group B: ranibizumab + PDT. *Chi-square test; P,0.05. łMann–Whitney U-test; P,0.05. §Previous treatment 6 months before inclusion. 
¥Previous treatment 3 months before inclusion.
Abbreviations: CNV, choroidal neovascularization; PDT, photodynamic therapy; RAP, retinal angiomatous proliferation; SD, standard deviation.
mean age was 79.4 years (standard deviation [SD] =6.1). 
At the time of inclusion, the most common RAP stage in both 
groups was stage II, which was present in six patients (60%) 
in group A and five patients (50%) in group B.
A total of six patients (three patients in group A and three 
patients in group B) had received some previous treatment 
for CNV in the study eye. Glaucoma was the most common 
previous ophthalmological condition in both groups in the non-
study eye. Prior cataract surgery on the study eye was recorded 
in five patients (50%) and two patients (20%) in groups A 
and B, respectively. The most frequent signs were the presence 
of epithelial pigment alterations (70% and 40%, respectively) 
and macular drusen (70% and 60%, respectively). Intraocular 
pressure was similar in both groups at baseline visit. The most 
common angiographic pattern in the study eye was minimally 
classic CNV in five patients of group A (50%) and occult CNV 
in five patients of group B (50%). OCT of the study eye at 
the time of inclusion showed five patients (50%) in group A 
and three patients (30%) in group B to have exudative retinal 
detachment, while eight patients (80%) and six patients (60%), 
respectively, presented cystoid macular edema.
No statistically significant differences were observed 
between the two groups for any of the characteristics 
analyzed – both being homogeneous in terms of the baseline 
clinical and biodemographic parameters.
Only two patients from group A were prematurely with-
drawn from the study due to informed consent withdrawal 
by a patient and the onset of a severe concomitant disease 
which affected the participation of another patient in the 
clinical trial.
Efficacy results
The principal efficacy variable or endpoint of the study was 
the mean change in BCVA after 6 and 12 months, calculated 
with respect to baseline VA values for the patients in both 
treatment groups. The results obtained for groups A and B 
were: 1.30 (95% confidence interval [CI]: -5.90 to 8.50) and 
7.60 (95% CI: 1.20–14.00) after 6 months of follow-up, and 
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1.50 (95% CI: -8.44 to 11.44) and 5.60 (95% CI: -2.30 to 
13.50) after 12 months of follow-up, with no statistically 
significant differences observed according to treatment group 
(ANOVA; P.0.05) (Figure 1).
The percentage of patients showing improved BCVA, 
defined as a VA improvement of over five, ten, and 15 letters 
after 6 and 12 months of follow-up, versus baseline was 
determined. After 6 months of follow-up, 40% of the patients 
(four patients) in both groups presented a VA increase of 
over five letters, 10% (one patient) in group A and 20% (two 
patients) in group B showed an improvement of over ten 
letters, and 10% (one patient) in group B showed a VA gain 
of over 15 letters. After 12 months of follow-up, 50% of the 
patients (five patients) in group A and 40% (four patients) 
in group B showed a VA increase of over five letters, 30% 
(three patients) in group A and 20% (two patients) in group B 
showed a gain of over ten letters, and 20% (two patients) 
in both groups showed an improvement of over 15 letters. 
No statistically significant differences were found between 
the two treatment groups or between the visits analyzed for 
each group (chi-square test; P.0.05) (Figure 2).
Regarding the evolution of VA, both groups showed 
statistically significant differences in the mean BCVA value 
versus baseline at visits 4 and 5 (months 4 and 5 of the trial) 
in group A, and at visits 4, 6, 7, and 11 (months 4, 6, 7, and 
11 of the trial) in group B (Student’s t-test; P,0.05).
Figure 1 Changes in mean best-corrected visual acuity at 6 and 12 months.
Note: Values in italics are P.0.05 (as calculated by analysis of variance).
Figure 2 Visual acuity improvement at 6 and 12 months.





The percentage of patients presenting a slight decrease 
in VA after 6 and 12 months of follow-up (defined as a 
loss of ,15 letters vs baseline) was 10% (one patient) in 
both groups at 6 months, while a slight decrease was only 
present in 10% of the patients (one patient) in group B after 
12 months. No significant differences were observed accord-
ing to treatment group or between the visits analyzed for each 
group (chi-square test; P.0.05).
There were no statistically significant differences between 
the treatment groups regarding the presence of exudative 
retinal detachment determined by OCT during the study with 
respect to baseline (chi-square test; P.0.05).
Mean change in greatest linear dimension and in CNV 
size, measured by FA, and the mean change in foveal 
thickness as determined by OCT, after 3, 6, and 12 months 
versus baseline were analyzed. No statistically significant 
differences between treatment groups or visits were observed 
within the same group (ANOVA; P.0.05) (Table 3).
Regarding the number of retreatments in the two groups, 
no statistically significant intergroup differences were 
detected – the mean number per patient being 1.8 (SD =1.5) 
in group A and 0.9 (SD =1.4) in group B (Mann–Whitney 
U-test; P.0.05). The RAP relapse rate was 80.0% in group A 
and 40.0% in group B, and the mean time to retreatment was 
3.1 months (SD =1.4) and 3.8 months (SD =0.0), respectively 
(Mann–Whitney U-test; P.0.05) (Table 4).
safety results
Forty-five percent of the patients experienced some AE (six 
subjects in group A and three in group B), with no statisti-
cally significant differences found between the two groups 
(chi-square test; P.0.05).
Table 3 evolution of morphological and functional characteristics
Group A (n=10) Group B (n=10) P-value1
Visual acuity, letters (mean ± SD)
Baseline 53.5±15.6 56.1±11.7 0.7653
3 months 57.7±20.1 61.0±16.0 1.0000
6 months 54.8±16.9 63.7±13.2° 0.3374
12 months 55.0±17.6 61.7±13.9 0.2680
Mean changes, letters* (mean ± SD) 1.3±10.1 7.6±8.9 0.7089
Foveal thickness, µm (mean ± SD)
Baseline 438.7±86.6 361.5±81.2 0.0891
3 months 211.1±103.4° 181.3±39.1° 0.6878
6 months 246.4±90.2° 226.8±52.4° 1.0000
12 months 215.5±25.9° 215.1±34.4° 1.0000
Mean changes (OCT),* µm (mean ± SD) -236.3±109.6 -146.4±91.0 0.1499
Lesion size, µm (mean ± SD)
Baseline 3,827.6±1,370.2 3,297.7±1,740.7 0.4965
3 months 1,719.3±2,067.3° 2,770.5±1,959.2° 0.2497
6 months 3,172.6±3,273.5 3,065.1±2,273.5 0.8340
12 months 3,268.6±3,149.1 3,738.7±2,231.2 0.6030
Mean changes (angiographic),* µm (mean ± SD) -622.9±3,003.3 207.9±1,078.7 0.4702
Total area of CNV, mm2 (mean ± SD)
Baseline 1.9±1.6 2.3±1.9 1.0000
3 months 0° 0.7±1.3° 0.0939
6 months 1.0±1.4 1.0±1.2 0.9135
12 months 1.8±2.8 1.2±1.8 1.0000
Mean changes (angiographic),* mm2 (mean ± SD) -0.013.6 -1.27±2.1 0.4104
Notes: Group A: ranibizumab; group B: ranibizumab + PDT. 1ANOVA test; P,0.05. °student’s t-test; P,0.05. *Mann–Whitney U-test; P,0.05.
Abbreviations: ANOVA, analysis of variance; CNV, choroidal neovascularization; OCT, optical coherence tomography; PDT, photodynamic therapy; SD, standard 
deviation.
Table 4 retreatment
Group A  
(n=10)
Group B  
(n=10)
P-value
number of retreatments  
(mean ± sD)*
1.8±1.5 0.9±1.4 0.1383
Time to retreatment,  
months (mean ± sD)*
3.1±1.4 3.8±0.0¥ 1.0000
relapse rate, n (%) 8 (80.0) 4 (40.0) 0.0679
Notes: Group A: ranibizumab; group B: ranibizumab + PDT. *Mann–Whitney U-test; 
P,0.05. ¥no data of visit 3 were available for one patient, so time to retreatment 
was calculated for three patients who received retreatment during visits 3–12.
Abbreviations: PDT, photodynamic therapy; SD, standard deviation.
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None of the AEs reported during the trial were considered 
to be related to the study drug. Most of the AEs had mild 
intensity (66.6% of those in group A and 100% of those in 
group B). The most frequent AEs were ear and labyrinth 
disorders (observed in two patients in group A and in one 
subject in group B) and ocular problems (seen in three cases 
in group B). In the course of the study, there was only one 
serious adverse event (SAE): the death of a patient in group A 
due to worsening of concomitant disease and not related to 
the study medication.
Discussion
RAP is considered to be a subtype of neovascular ARMD,1 
differing from the latter in terms of the course of condition 
and response to treatment,7 with a poorer prognosis due 
to the absence of standardized treatment up to date.1,9,23 
Therefore, any strategy offering stabilization or improve-
ment constitutes an advancement in the management of 
the disease. In this sense, the contribution of this study 
with respect to previous studies on RAP is based upon its 
design. The present study is a prospective one with stratified 
randomization for both treatment regimens (ranibizumab in 
monotherapy or ranibizumab plus PDT with verteporfin) 
according to the stage of the disease, resulting in comparable, 
homogeneous groups.
In the present study, although no significant differences 
were observed between the groups regarding the analyzed 
efficacy variables, both treatment groups showed a tendency 
toward an increase in mean BCVA scores versus baseline 
values, after both 6 and 12 months of follow-up. This 
improvement in VA was greater in group B than in patients 
administered monotherapy (at 12 months: 5.60 letters vs 
1.50 letters) (Figure 1). After 12 months, 20% of the patients 
in both treatment groups showed a VA improvement of over 
three lines, and 30% and 20%, respectively, showed more than 
two lines of gain in VA versus the baseline visit (Figure 2).
Starting in the fourth month of the study, a statistically 
significant increase in mean BCVA was noted versus baseline 
in both groups. At this point, ranibizumab loading phase 
had already ended, and thus, at least three intravitreous 
injections of the drug had been administered in both groups. 
Similar results were reported in a retrospective case review 
of 26 patients treated with ranibizumab 0.5 mg,18 where 31% 
of patients showed a BCVA increment of over three lines 
after receiving the first three intravitreous injections of the 
loading phase.
In the present study and throughout the duration of 
follow-up, no statistically significant differences were 
observed between the treatment groups regarding the mor-
phological changes in the retina as determined by FA or ICG 
(surface of the lesion or of the CNV) or in central foveal 
thickness as evidenced by OCT. However, on analyzing the 
mean change in foveal thickness, a decrease was observed 
in months 3, 6, and 12 versus baseline, thus suggesting a 
tendency toward improvement in both treatment groups, with 
comparatively greater improvement found in the ranibizumab 
monotherapy group.
Rouvas et al24 have published a randomized prospective 
trial with a 12-month follow-up, comparing the efficacy of 
three treatments: ranibizumab 0.5 mg in monotherapy (n=13) 
or in combination with PDT with verteporfin (n=13), and a 
combination of intravitreous triamcinolone with PDT with 
verteporfin (n=11); the criterion used for retreatment was the 
presence of sub- or intraretinal exudate.
In a similar way to our study, the above-mentioned 
study reported VA stabilization in all treatment groups at 
the end of follow-up, with no statistically significant dif-
ferences between groups. In this context, combination of 
triamcinolone and PDT showed the best results, with no 
differences between the other two treatment groups. Like-
wise, the authors detected no differences in terms of the 
number of retreatments required by the patients adminis-
tered ranibizumab in monotherapy (3.07) or in combination 
with PDT (0.46).24 In the present study, the mean number 
of retreatments in monotherapy group was almost one half 
after 12 months follow-up (1.8). This difference between 
monotherapy and combined therapy may be due to the time 
of retreatment administration according to protocol; intra-
vitreal injection of ranibizumab could be administered every 
30 days, while ranibizumab plus PDT should be administered 
every 90 days.
Regarding foveal thickness, Rouvas et al24 reported a 
decrease in all treatment groups, though significance was 
only reached in groups receiving combined therapy (ranibi-
zumab with PDT and triamcinolone with PDT), which 
differed from our results wherein patients administered 
ranibizumab in monotherapy showed the most important 
anatomical changes.
Despite the differences between the two trials in terms of 
design, patient profile, method used for VA evaluation, and 
the treatment scheme employed, the results of the present 
study were similar to those published by Rouvas et al.24 The 
following should be noted: the latter study did not perform 
stratified randomization to therapy according to RAP stage; 
the VA measurements were based on a nonstandardized 
Snellen chart; all of the analyzed patients were naïve to 





treatment for CNV in the study eye; and the groups were 
not homogeneous in terms of RAP stage. In the present 
study, 30% of the patients in both groups had received 
some previous treatment for CNV in the study eye – a fact 
that may lead to a lower improvement observed during 
follow-up in terms of VA and foveal thickness. In this trend, 
Reche-Frutos et al27 had reported results from a prospec-
tive trial performed in non-naïve patients with RAP treated 
with ranibizumab in monotherapy at different stages. Their 
results suggested that a higher percentage of patients with 
previous treatment and a lower baseline VA could indicate 
a longer time of disease progression and greater structural 
involvement of the retina; so, a poorer response could be 
expected. In Reche-Frutos et al’s study, all patients with no 
relapse of RAP after 12 months were in stage IIA of RAP, 
which indicates that monotherapy with ranibizumab could 
provide better response in patients with more superficial 
lesions. Confirming these findings, in the present study, 
only 20% of patients in the group treated with monotherapy 
showed no relapse in RAP lesion; this group showed majorly 
RAP stage II at baseline. Also, 30% of patients had received 
previous treatment on the study eye.
More recently, Saito et al28 reported a retrospective case 
series review on patients with RAP who were naïve to treat-
ment and majorly in RAP stage II and were treated with a 
combination of ranibizumab intravitreal injection and PDT 
with verteporfin; an increase of three lines or more in BCVA 
was reached in 50% of the treated eyes after 12 months of 
follow-up, in comparison with the results of the present study 
where only 20% of eyes treated with the combined treatment 
showed a similar increase in BCVA at 12 months.
Present data indicate that both studied treatments sta-
bilized VA and foveal thickness after 6 and 12 months of 
follow-up, as shown by positive values obtained in the mean 
change in BCVA and negative values in the mean change 
in foveal thickness for both treatment groups. The results 
are in agreement with the results reported in a number of 
studies on ranibizumab in monotherapy18–20,27 or in combina-
tion with PDT.24,28,29 In this sense, the observed functional 
improvement (VA) proved greater for the combination of 
ranibizumab plus PDT with verteporfin, while from the 
anatomical perspective (foveal thickness), the greatest reduc-
tion corresponded to the group administered ranibizumab in 
monotherapy. This finding differs from the observations of 
other studies in which functional and anatomical improve-
ment showed the same trend.18–20,24,28,30 Among other factors, 
this discrepancy may be due to the different profiles of the 
patients included in these studies, where subjects had not 
received previous treatment in the study eye and the initial 
RAP stage differed.
For a long time, PDT with verteporfin has been con-
sidered the gold standard treatment for RAP,7,9,12 despite 
the scanty encouraging results obtained. However, PDT 
in combination with other drugs (antiangiogenic agents or 
corticosteroids)14,15,17,22–24 might be a better approach for the 
treatment of advanced RAP lesions. Results obtained from 
recent studies seem to indicate that combined therapy consist-
ing of intravitreal ranibizumab and PDT might require fewer 
treatments than an anti-VEGF agent in monotherapy.28,31 
On the other hand, studies with bevacizumab22,23 in mono-
therapy or combined with verteporfin report results similar 
to those obtained in the present study, pointing to the com-
bination treatment as a viable alternative in the management 
of RAP.
Regarding safety, no serious AEs related to the study drug 
were reported, and both groups showed a similar safety pro-
file. These observations coincide with the available literature 
on ranibizumab 0.5 mg used to treat this disorder.18–20,27,30
The main limitation of this study is that only 20 of the 30 
initially planned subjects could be recruited due to the dif-
ficulty in identifying eligible patients. Nevertheless, the total 
number of subjects per group was similar to that of the only 
randomized trial published to date on ranibizumab and related 
to this condition.24 In addition, the stratified randomization 
according to RAP stage, the inclusion of patients previously 
treated for CNV, and the use of standardized methods to 
assess efficacy and safety give validity to the present study 
results obtained with ranibizumab in monotherapy or com-
bined with PDT with verteporfin in the treatment of RAP.
Conclusion
Results obtained in the present study warrant the need for 
randomized trials including a larger number of patients per 
treatment group, with a more representative profile of this 
disease, as seen by retinal specialists in clinical practice, 
and which may provide enough evidence for establishing an 
optimum treatment for RAP. Present study findings suggest 
that ranibizumab may be a valid therapeutic alternative in 
the management of RAP.
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